Clinical Trials Logo

Clinical Trial Summary

Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial.

Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.

Clinical Trial Description

Background: Non small-cell lung cancer (NSCLC) is a common disease with a poor prognosis when locally advanced or metastasized, despite advances in surgery, chemo- and radiation therapy.

In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.

IDO has recently been recognized as an important factor in immune regulation and development of immune tolerance in the microenvironment of cancer cells. Cells that represent IDO at their surface are known to inhibit the immune system. IDO expression is seen both in cancer cells and antigen presenting cells. The vaccination against IDO expressing cells is therefore two-sided. The vaccination therapy is thought to block the development of immune tolerance induced by IDO expressing cells. At the same time the investigators aim to stimulate the production of IDO specific T-cells, hence facilitating the elimination of IDO positive tumour cells. The primary end points are safety and toxicity evaluation. Secondary end points are immunological and clinical response. ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

NCT number NCT01219348
Study type Interventional
Source Herlev Hospital
Status Completed
Phase Phase 1
Start date June 2010
Completion date August 2012

See also
  Status Clinical Trial Phase
Recruiting NCT02513563 - AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Phase 2
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study N/A
Active, not recruiting NCT02538666 - An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Phase 3
Active, not recruiting NCT02196844 - Yoga Program for Lung Cancer Patients and Caregivers N/A
Recruiting NCT03317080 - Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer N/A
Recruiting NCT02429843 - A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer Phase 1
Recruiting NCT03305978 - Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan. N/A
Not yet recruiting NCT03346304 - Photodynamic Therapy for the Prevention of Lung Cancer Phase 2/Phase 3
Recruiting NCT03009630 - ENB Guided RFA for Early-stage Peripheral Lung Cancer N/A
Recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Recruiting NCT03050047 - A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT02939729 - Physiotherapy Prehabilitation in Patients Undergoing Cardiac or Thoracic Surgery N/A
Recruiting NCT02903914 - Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT02795923 - Nivolumab Alone or in Combination With Decitabine/Tetrahydrouridine in Non-small Cell Lung Cancer Phase 2
Recruiting NCT02444741 - MK-3475 and Stereotactic Body Radiation Therapy (SBRT) in Patients With Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Recruiting NCT02507778 - Circulating Tumor Cells Spillage After Pulmonary Biopsy N/A
Recruiting NCT02308709 - Novel Lung Functional Imaging for Personalized Radiotherapy N/A
Completed NCT02771470 - Intestinal Microflora in Lung Cancer After Chemotherapy Phase 1
Completed NCT02233842 - Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors N/A